Cargando…

CAR-NK Cells: From Natural Basis to Design for Kill

Chimeric antigen receptors (CARs) are fusion proteins with an extracellular antigen recognition domain and numerous intracellular signaling domains that have been genetically modified. CAR-engineered T lymphocyte-based therapies have shown great success against blood cancers; however, potential fata...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khawar, Muhammad Babar, Sun, Haibo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712563/ https://www.ncbi.nlm.nih.gov/pubmed/34970253 http://dx.doi.org/10.3389/fimmu.2021.707542

Ejemplares similares

Neoantigens and NK Cells: “Trick or Treat” the Cancers?
por: Lv, Dan, et al.
Publicado: (2022)

From barriers to novel strategies: smarter CAR T therapy hits hard to tumors
por: Khawar, Muhammad Babar, et al.
Publicado: (2023)

Bryostatin Activates CAR T-Cell Antigen-Non-Specific Killing (CTAK), and CAR-T NK-Like Killing for Pre-B ALL, While Blocking Cytolysis of a Burkitt Lymphoma Cell Line
por: Wang, Lingyan, et al.
Publicado: (2022)

Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy
por: Ruppel, Katharina Eva, et al.
Publicado: (2022)

Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer
por: Nersesian, Sarah, et al.
Publicado: (2019)

Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy
por: Kilgour, Marisa K., et al.
Publicado: (2023)

Human CAR NK Cells: A New Non-viral Method Allowing High Efficient Transfection and Strong Tumor Cell Killing
por: Ingegnere, Tiziano, et al.
Publicado: (2019)

Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
por: Heipertz, Erica L., et al.
Publicado: (2021)

Preclinical assessment of CAR-NK cell-mediated killing efficacy and pharmacokinetics in a rapid zebrafish xenograft model of metastatic breast cancer
por: Murali Shankar, Nivedha, et al.
Publicado: (2023)

New insights into CAR T cell-mediated killing of tumor cells
por: Espie, David, et al.
Publicado: (2022)

Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells
por: Morgan, Michael A., et al.
Publicado: (2020)

Overcoming tumor resistance mechanisms in CAR-NK cell therapy
por: Valeri, Antonio, et al.
Publicado: (2022)

Preclinical and clinical studies of CAR-NK-cell therapies for malignancies
por: Li, Hongwen, et al.
Publicado: (2022)

Efficient Killing of Murine Pluripotent Stem Cells by Natural Killer (NK) Cells Requires Activation by Cytokines and Partly Depends on the Activating NK Receptor NKG2D
por: Gröschel, Carina, et al.
Publicado: (2017)

DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy
por: Cifaldi, Loredana, et al.
Publicado: (2023)

Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy
por: Yang, Kangdi, et al.
Publicado: (2023)

Engineering NK Cells for CAR Therapy—Recent Advances in Gene Transfer Methodology
por: Schmidt, Paula, et al.
Publicado: (2021)

Complement-Opsonized HIV-1 Alters Cross Talk Between Dendritic Cells and Natural Killer (NK) Cells to Inhibit NK Killing and to Upregulate PD-1, CXCR3, and CCR4 on T Cells
por: Ellegård, Rada, et al.
Publicado: (2018)

NK Cells Equipped With a Chimeric Antigen Receptor That Overcomes Inhibition by HLA Class I for Adoptive Transfer of CAR-NK Cells
por: Zhuang, Xiaoxuan, et al.
Publicado: (2022)

A bibliometric and scientific knowledge-map study of the chimeric antigen receptor (CAR) natural killer (NK) cell-related research from 2010 to 2022
por: Zhang, Juan, et al.
Publicado: (2022)

Editorial: The mechanism and novel strategies of overcoming resistance of hematological malignancies to CAR-T cell killing
por: Zhang, Tingting, et al.
Publicado: (2022)

Glycoprotein Targeted CAR-NK Cells for the Treatment of SARS-CoV-2 Infection
por: Christodoulou, Ilias, et al.
Publicado: (2021)

Highly Efficient Generation of Transgenically Augmented CAR NK Cells Overexpressing CXCR4
por: Jamali, Arezoo, et al.
Publicado: (2020)

Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies
por: Soldierer, Maren, et al.
Publicado: (2022)

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells
por: Tian, Xiaopeng, et al.
Publicado: (2023)

Structural Basis for Recognition of Cellular and Viral Ligands by NK Cell Receptors
por: Li, Yili, et al.
Publicado: (2014)

CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo
por: Golubovskaya, Vita, et al.
Publicado: (2023)

Tissue-resident natural killer (NK) cells are cell lineages distinct from thymic and conventional splenic NK cells
por: Sojka, Dorothy K, et al.
Publicado: (2014)

Activated Allogeneic NK Cells Preferentially Kill Poor Prognosis B-Cell Chronic Lymphocytic Leukemia Cells
por: Sánchez-Martínez, Diego, et al.
Publicado: (2016)

An Historical Overview: The Discovery of How NK Cells Can Kill Enemies, Recruit Defense Troops, and More
por: Vitale, Massimo, et al.
Publicado: (2019)

Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells
por: Klingemann, Hans, et al.
Publicado: (2016)

Data driven model discovery and interpretation for CAR T-cell killing using sparse identification and latent variables
por: Brummer, Alexander B., et al.
Publicado: (2023)

“Natural Regulators”: NK Cells as Modulators of T Cell Immunity
por: Schuster, Iona S., et al.
Publicado: (2016)

CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy
por: Burger, Michael C., et al.
Publicado: (2019)

CAR-NK Cells Effectively Target SARS-CoV-2-Spike-Expressing Cell Lines In Vitro
por: Ma, Minh Tuyet, et al.
Publicado: (2021)

Non-Genetically Improving the Natural Cytotoxicity of Natural Killer (NK) Cells
por: Villalba, Martin, et al.
Publicado: (2020)

CAR T Cells Targeting Membrane-Bound Hsp70 on Tumor Cells Mimic Hsp70-Primed NK Cells
por: Bashiri Dezfouli, Ali, et al.
Publicado: (2022)

Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
por: Gong, Ying, et al.
Publicado: (2021)

The Smac Mimetic BV6 Improves NK Cell-Mediated Killing of Rhabdomyosarcoma Cells by Simultaneously Targeting Tumor and Effector Cells
por: Fischer, Kyra, et al.
Publicado: (2017)

Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas
por: Zuo, Pengcheng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6edtvg71cn9od0hklg3vd8oqgc